Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2017 Mar 12

PMID 28283950

Citations 20

Authors

Richard Van Krieken

Joan C Krepinsky

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Diabetic nephropathy, a major microvascular complication of diabetes and the most common cause of end-stage renal disease, is characterized by prominent accumulation of extracellular matrix. The membrane microdomains caveolae, and their integral protein caveolin-1, play critical roles in the regulation of signal transduction. In this review we discuss current knowledge of the contribution of caveolin-1/caveolae to profibrotic signaling and the pathogenesis of diabetic kidney disease, and assess its potential as a therapeutic target.

Recent Findings: Caveolin (cav)-1 is key to facilitating profibrotic signal transduction induced by several stimuli known to be pathogenic in diabetic nephropathy, including the most prominent factors hyperglycemia and angiotensin II. Phosphorylation of cav-1 on Y14 is an important regulator of these responses. In vivo studies support a pathogenic role for caveolae in the progression of diabetic nephropathy. Targeting caveolin-1/caveolae would enable inhibition of multiple profibrotic pathways, representing a novel and potentially potent therapeutic option for diabetic nephropathy.

Citing Articles

The critical roles of caveolin-1 in lung diseases.

Fan J, Zheng S, Wang M, Yuan X Front Pharmacol. 2024; 15:1417834.

PMID: 39380904 PMC: 11458383. DOI: 10.3389/fphar.2024.1417834.

Interplay between caveolin-1 and mineralocorticoid receptor in cardiometabolic disease.

Czarzasta K, Pojoga L J Endocrinol. 2024; 262(3).

PMID: 38916410 PMC: 11813230. DOI: 10.1530/JOE-23-0341.

Increased Levels of Circulating IGFBP4 and ANGPTL8 with a Prospective Role in Diabetic Nephropathy.

AlMajed H, Abu-Farha M, Alshawaf E, Devarajan S, Alsairafi Z, Elhelaly A Int J Mol Sci. 2023; 24(18).

PMID: 37762544 PMC: 10531667. DOI: 10.3390/ijms241814244.

The Jiangtang Tongmai Prescription Inhibits Inflammation and Fibrosis of Lung Fibroblast Autophagy Induced by Hyperglycemia by Regulating CAV1 Expression.

Ding N, Fan Y, Zheng C Endocr Metab Immune Disord Drug Targets. 2023; 24(6):717-724.

PMID: 37622706 DOI: 10.2174/1871530323666230824165645.

Overexpression of Plasmalemmal Vesicle-Associated Protein-1 Reflects Glomerular Endothelial Injury in Cases of Proliferative Glomerulonephritis with Monoclonal IgG Deposits.

Sawada A, Kawanishi K, Igarashi Y, Taneda S, Hattori M, Ishida H Kidney Int Rep. 2023; 8(1):151-163.

PMID: 36644361 PMC: 9831946. DOI: 10.1016/j.ekir.2022.10.010.

References

Grande G, Rippe C, Rippe A, Rahman A, Sward K, Rippe B . Unaltered size selectivity of the glomerular filtration barrier in caveolin-1 knockout mice. Am J Physiol Renal Physiol. 2009; 297(2):F257-62. DOI: 10.1152/ajprenal.00075.2009. View

Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N . A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 2007; 192(3):595-603. DOI: 10.1677/JOE-06-0045. View

Heilig C, Deb D, Abdul A, Riaz H, James L, Salameh J . GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy. Am J Nephrol. 2013; 38(1):39-49. DOI: 10.1159/000351989. View

Perlman A, Lawsin L, Kolachana P, Saji M, Moore Jr J, Ringel M . Angiotensin II regulation of TGF-beta in murine mesangial cells involves both PI3 kinase and MAP kinase. Ann Clin Lab Sci. 2004; 34(3):277-86. View

Komers R . Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol. 2013; 76(4):551-9. PMC: 3791978. DOI: 10.1111/bcp.12196. View

Parton R, Simons K . The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007; 8(3):185-94. DOI: 10.1038/nrm2122. View

Castrop H, Schiessl I . Novel routes of albumin passage across the glomerular filtration barrier. Acta Physiol (Oxf). 2016; 219(3):544-553. DOI: 10.1111/apha.12760. View

Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R . Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008; 294(5):L843-61. DOI: 10.1152/ajplung.00295.2007. View

Ohshiro Y, Ma R, Yasuda Y, Hiraoka-Yamamoto J, Clermont A, Isshiki K . Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes. 2006; 55(11):3112-20. DOI: 10.2337/db06-0895. View

10.

Forbes J, Fukami K, Cooper M . Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007; 115(2):69-84. DOI: 10.1055/s-2007-949721. View

11.

Wang L, Zhang C, Su X, Lin D, Wang W . Caveolin-1 Deficiency Inhibits the Basolateral K+ Channels in the Distal Convoluted Tubule and Impairs Renal K+ and Mg2+ Transport. J Am Soc Nephrol. 2015; 26(11):2678-90. PMC: 4625665. DOI: 10.1681/ASN.2014070658. View

12.

Zhang B, Peng F, Wu D, Ingram A, Gao B, Krepinsky J . Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells. Cell Signal. 2007; 19(8):1690-700. DOI: 10.1016/j.cellsig.2007.03.005. View

13.

Denhez B, Lizotte F, Guimond M, Jones N, Takano T, Geraldes P . Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes. J Biol Chem. 2014; 290(1):350-8. PMC: 4281738. DOI: 10.1074/jbc.M114.612721. View

14.

Zidovetzki R, Levitan I . Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta. 2007; 1768(6):1311-24. PMC: 1948080. DOI: 10.1016/j.bbamem.2007.03.026. View

15.

Demova H, Komers R . Determination of caveolin-1 in renal caveolar and non-caveolar fractions in experimental type 1 diabetes. Physiol Res. 2008; 58(4):563-568. DOI: 10.33549/physiolres.931369. View

16.

Wang X, Zhang Y, Kim H, Zhou Z, Feghali-Bostwick C, Liu F . Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006; 203(13):2895-906. PMC: 1850940. DOI: 10.1084/jem.20061536. View

17.

Gorin Y, Block K . Nox as a target for diabetic complications. Clin Sci (Lond). 2013; 125(8):361-82. DOI: 10.1042/CS20130065. View

18.

Arya A, Yadav H, Sharma P . Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats. Mol Cell Biochem. 2011; 354(1-2):57-66. DOI: 10.1007/s11010-011-0805-6. View

19.

Percy C, Waters M, Gobe G . Caveolins in the repair phase of acute renal failure after oxidative stress. Nephrology (Carlton). 2005; 9(6):374-80. DOI: 10.1111/j.1440-1797.2004.00356.x. View

20.

Woodman O, Missen M, Boujaoude M . Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1. J Cardiovasc Pharmacol. 2004; 44(2):155-63. DOI: 10.1097/00005344-200408000-00003. View